Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
BRIEF-AbbVie Inc Q2 Adjusted EPS USD 3.65 Vs. IBES Estimate USD 3.6

BRIEF-AbbVie Inc Q2 Adjusted EPS USD 3.65 Vs. IBES Estimate USD 3.6

ReutersReuters2026/07/31 11:48

Jul 31 (Reuters) - AbbVie Inc Q2 Global Skyrizi revenue USD 5,505 million.

  • Q2 Global Rinvoq revenue USD 2,525 million
  • Q2 EPS USD 2.03
  • Q2 revenue USD 16,990 million vs. IBES estimate USD 16,765 million
  • Q2 Global Humira revenue USD 756 million
  • outlook FY adjusted EPS USD 0.14 vs. IBES estimate USD 14.1
  • ABBVIE : Q2 RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.17/SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE
  • ABBVIE : FY 2026 ADJ EPS GUIDANCE INCLUDES $0.14 /SHARE DILUTIVE IMPACT RELATED TO ACQUISITION OF APOGEE THERAPEUTICS
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!